首页> 外文期刊>Nephron >Clinical Outcome and Prognosis of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Japan
【24h】

Clinical Outcome and Prognosis of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in Japan

机译:日本抗中性粒细胞胞浆抗体相关性血管炎的临床疗效及预后

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: We conducted a broad survey of 99 patients with anti-neutrophil cytoplasmic antibody (ANCA)-as-sociated vasculitis and investigated both prognosis and outcomes. Methods: Clinical data evaluated were age, sex, patient survival, renal survival, serum albumin, serum cre-atinine, urinary protein, hematuria, C-reactive protein (CRP), ANCA titer, IgG and the Birmingham Vasculitis Activity Score (BVAS). Results: The patient survival rate at 6 months after onset was 84.8%, and that at 2 years after onset was 82.0%. Most deaths were within 6 months of onset. Infection accounted for 9 deaths (60.0%). Infection together with pulmonary involvement of active vasculitis accounted for 2 deaths (13.3%). Organ-specific involvement of active vasculitis alone caused 3 deaths (20.0%). Others died of cardiac events. At 1 and 3 months after onset, BVAS (p < 0.0001, p = 0.002), albumin (p = 0.006, p = 0.0004) and CRP (p = 0.04, p = 0.0002) were also associated with patient death. Concluimprove the prognosis of those with ANCA-associ-ated vasculitis, the intensity of initial treatment should be aimed at disease severity. Employing BVAS improved the ability to evaluate therapeutic responses. Finally, prescription with sulfamethoxazole-trimethoprim during the induction therapy with immunosuppressive agents may be advised.
机译:背景/目的:我们对99名抗中性粒细胞胞浆抗体(ANCA)相关性血管炎患者进行了广泛调查,并调查了预后和结果。方法:评估的临床数据包括年龄,性别,患者存活率,肾脏存活率,血清白蛋白,血清肌酐,尿蛋白,血尿,C反应蛋白(CRP),ANCA滴度,IgG和伯明翰血管炎活性评分(BVAS) 。结果:发病后6个月的患者生存率为84.8%,发病后2年的患者生存率为82.0%。大多数死亡发生在发病后的6个月内。感染导致9人死亡(60.0%)。感染与活动性血管炎的肺部感染一起导致2例死亡(13.3%)。仅活动性血管炎的器官特异性累及就导致3例死亡(20.0%)。其他人死于心脏事件。发病后1和3个月,BVAS(p <0.0001,p = 0.002),白蛋白(p = 0.006,p = 0.0004)和CRP(p = 0.04,p = 0.0002)也与患者死亡相关。结论改善ANCA相关血管炎患者的预后,初始治疗的强度应针对疾病的严重程度。使用BVAS可以提高评估治疗反应的能力。最后,建议在用免疫抑制剂诱导治疗期间用磺胺甲恶唑-三甲氧苄啶处方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号